BIOPHYTIS : Invitation

Lovimi

01 oct. 2021 •20:56

Dear Investor, dear shareholder,
Biophytis is a Euronext and Nasdaq listed late-stage biotech company based in Paris (www.biophytis.com) with advanced assets currently in phase 2b in Sarcopenia, and in phase 2/3 in severe respiratory manifestations linked to Covid-19.
We recently achieved significant clinical progresses:
- COVA, our phase 2-3 study in COVID-19 has received positive feedback from DMC on the 2nd interim analysis, being safe and in the promising zone for efficacy
- SARA, our phase 2b study in Sarcopenia has demonstrated clinically meaningful efficacy
Our next inflection point milestones are reporting the full results from COVA study and filling for Emergency Use Approval/Conditional Approval in Q2 2022, targeting a potential commercialization for COVID-19 treatment mid-2022. In Sarcopenia, we are currently preparing our meetings with FDA/EMA in order to design the Phase 3 program by Q4 2021 and initiate clinical activities in 2022. We are currently active in partnership discussions for both indications to trigger new values.
We'd like to invite you to our next KOLs event and will be delighted to share more information and answer to your questions on these two projects during this full digital event to be held on Oct, 6th 2021, and organized as a two-session event. Please see below overall agenda, participants and registration link.
Session 1- COVA project in COVID-19
• Oct 6th, 5.30 to 6.15pm, CET
• KOLs: Dr Girish Balachandran Nair (USA) and Pr Suzana Lobo (Brazil)
• Biophytis representatives: Stanislas Veillet (CEO), Rob Van Maanen (CMO) and Evelyne Nguyen (CFO)
Session 2- SARA project in Sarcopenia
• Oct 6th, 6.45 to 7.30pm, CET
• KOLs: Pr Bruno Vellas (France) and Dr Roger A. Fielding (USA)
• Biophytis representatives: Stanislas Veillet (CEO), Pr Jean Mariani (Scientific Advisory Board President)
and Evelyne Nguyen (CFO)
Agenda for each session & Registration for Event
• Introductory remarks: 5 min- Stanislas Veillet (CEO)
• Presentation of unmet medical need and treatment landscape: 15 min- KOLs
• Biophytis update: 10 min- Rob Van Maanen (COVA), Jean Mariani (SARA)
• Q&A session: 15 min- invited investors
• Closing remarks: 1 min- CEO
Registration link: please register at this link before the event Q&A session
https://www.financelive.fr/biophytis/inscription/ Send questions at (+33) 07.69.72.74.75 or ask questions in the Chat, during the live!

Key Opinion Leaders (KOLs)
Pr Suzana-Margareth-Ajeje-Lobo, MD
• Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto
• São Jose do Rio Preto – São Paulo State, Brazil
Dr Girish Balachandran Nair, MD
• Associate Professor of Medicine in the division of Pulmonary and Critical Care at Beaumont Health. Medical Director of the Interstitial Lung Disease (ILD) program and the Associate Program Director for the Pulmonary and Critical Care Fellowship at Beaumont Hospital
• Royal Oak, USA
Pr Bruno Vellas, MD, PhD
• Chair of the Gerontopole
• University of Toulouse
• Toulouse, France
Dr Roger A. Fielding, Ph.D.
• Associate Center Director, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
• Director and Senior Scientist, Nutrition, Exercise Physiology, and Sarcopenia Laboratory
• Professor of Nutrition and Medicine, Friedman School of Nutrition Science and Policy, Tufts
University School of Medicine
• Associate Director, Boston Claude D. Pepper Older Americans Independence Center Bost